An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly
NCT ID: NCT01995734
Last Updated: 2015-12-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
APPROVED_FOR_MARKETING
EXPANDED_ACCESS
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pasireotide long acting release formulation
Pasireotide LAR will be administered intramuscularly (i.m.) every 28 days until pasireotide becomes commercially available and reimbursed or until 31 December 2015, whichever occurs first.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who are not controlled by pituitary surgery or who are not eligible for or refuse surgery.
* For patients on medical treatment for acromegaly the following washout periods must be completed before screening assessments are performed:
* Dopamine agonists (bromocriptine, cabergoline): 4 weeks
* GH-receptor antagonists (pegvisomant): 8 weeks
* Somatostatin analogues: no washout period required
* Karnofsky performance status ≥ 60.
Exclusion Criteria
* Concomitant treatment with growth hormone receptor (GHR)-antagonists or dopamine agonists unless concomitant treatment was discontinued and the washout period was completed before the screening assessments are performed.
* Patients with compression of the optic chiasm causing any visual field defect for whom surgical intervention is indicated.
* Patients who require a surgical intervention for relief of any sign or symptom associated with tumor compression.
* Patients who have undergone major surgery/surgical therapy for any cause within 4 weeks of screening.
* Patients who have received radiotherapy of the pituitary within 4 weeks prior to screening or have not recovered from side effects of radiotherapy.
* Patients who have a history of hypothyroidism and who are not adequately treated with stable doses of thyroid hormone replacement therapy.
* Patients with active malignant disease within the last five years (with the exception of basal cell carcinoma or carcinoma in situ of the cervix).
* Diabetic patients whose blood glucose is poorly controlled.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham Univ. of Alabama Birmingham
Birmingham, Alabama, United States
Advanced Research, LLC Advanced Reserch (4)
Peoria, Arizona, United States
St. Joseph's Hospital Medical Center St. Joseph's Hosp Med Ctr (2)
Phoenix, Arizona, United States
San Diego Coastal Endocrinology Group
Chula Vista, California, United States
University of Southern California Keck School of Medicine
Los Angeles, California, United States
University of California at Los Angeles UCLA - Los Angeles
Los Angeles, California, United States
John Wayne Cancer Institute Saint John's Health Center
Santa Monica, California, United States
Harbor-UCLA Medical Center Center for Men's Health
Torrance, California, United States
George Washington University Medical Center Medical Faculty Associates Inc
Washington D.C., District of Columbia, United States
Center for Diabetes & Endocrine Care Dept.of Ctr for Diab&Endoc - 2
Hollywood, Florida, United States
Central Florida Endocrine & Diabetes Consultants
Maitland, Florida, United States
Endocrine Assoc of FL
Ocoee, Florida, United States
Emory University School of Medicine/Winship Cancer Institute Emory University (5)
Atlanta, Georgia, United States
Dr. Steven Leichter, Endocrine Consultant
Columbus, Georgia, United States
Northwestern University Endo, Metabolism and Molecular
Chicago, Illinois, United States
The Johns Hopkins University School of Medicine Johns Hopkins University
Baltimore, Maryland, United States
Sinai Hospital of Baltimore Sinai Hospital, Baltimore
Baltimore, Maryland, United States
Tufts Medical Center Tufts Medical Ctr
Boston, Massachusetts, United States
Mayo Clinic - Rochester Mayo Clinic (2)
Rochester, Minnesota, United States
Washington University
St Louis, Missouri, United States
PALM MEDICAL RESEARCH CENTER Palm Research Center, Inc
Las Vegas, Nevada, United States
Robert Wood Johnson Medical School Div. Endo, Meta & Nutrition
New Brunswick, New Jersey, United States
University of New Mexico School of Medicine Univ of NM
Albuquerque, New Mexico, United States
Stony Brook Internists PC
East Setauket, New York, United States
Mount Sinai School of Medicine Mt. Sinai Schoof of Med.
New York, New York, United States
Columbia University Medical Center- New York Presbyterian Neuroendocrine Unit
New York, New York, United States
Endocrine Associates of Long Island, P.C.
Smithtown, New York, United States
Endocrinology Associates Inc
Columbus, Ohio, United States
Toledo Clinic Toledo Clinic, Inc.
Toledo, Ohio, United States
Oregon Health & Sciences University Oregon Health & Sciences
Portland, Oregon, United States
Thomas Jefferson University Jefferson University Physician
Philadelphia, Pennsylvania, United States
Allegheny Endocrinology Associates Allegheny Endo Associates
Pittsburgh, Pennsylvania, United States
MidState Endocrine Associates
Nashville, Tennessee, United States
Vanderbilt University Medical Center Clinical Trials Center
Nashville, Tennessee, United States
Baylor College of Medicine Division of Endocrinology
Houston, Texas, United States
Virginia Endocrinology Research
Chesapeake, Virginia, United States
Swedish Cancer Institute Swedish Neuroscience Institute
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Jerkins TW, Jerkins RK, Franklin R. Successful debulking of plurihormonal pituitary macroadenoma with long-acting pasireotide and dopamine agonist combination therapy. Clin Case Rep. 2019 Jan 28;7(3):445-451. doi: 10.1002/ccr3.1961. eCollection 2019 Mar.
Lovato CM, Kapsner PL. Analgesic effect of long-acting somatostatin receptor agonist pasireotide in a patient with acromegaly and intractable headaches. BMJ Case Rep. 2018 Jun 19;2018:bcr2017219686. doi: 10.1136/bcr-2017-219686.
Gordon MB, Nakhle S, Ludlam WH. Patients with Acromegaly Presenting with Colon Cancer: A Case Series. Case Rep Endocrinol. 2016;2016:5156295. doi: 10.1155/2016/5156295. Epub 2016 Nov 29.
Fleseriu M, Rusch E, Geer EB; ACCESS Study Investigators. Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study. Endocrine. 2017 Jan;55(1):247-255. doi: 10.1007/s12020-016-1182-4. Epub 2016 Nov 28.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CSOM230CUS33
Identifier Type: -
Identifier Source: org_study_id